![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Adis International
ISSN: 0114-9954
Source: Reactions Weekly, Vol.1, Iss.1130, 2006-01, pp. : 2-2
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
VTE risk included in the new safety information about Evra
Inpharma, Vol. 1, Iss. 1566, 2006-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Reactions Weekly, Vol. 1, Iss. 1092, 2006-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Third-generation OCs: increased VTE risk supported by new analyses
Inpharma, Vol. 1, Iss. 1264, 2000-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Ximelagatran reduces risk of VTE
Inpharma, Vol. 1, Iss. 1375, 2003-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Antipsychotics associated with elevated VTE risk
Reactions Weekly, Vol. 1, Iss. 1321, 2010-01 ,pp. :